Arvinas (ARVN) Q2 2026 earnings review
Platform Validated, but Pipeline Strategy Shifts Dramatically
Arvinas achieved the ultimate milestone: the FDA approval of VEPPANU, the first-ever PROTAC degrader. However, the resulting $249.7M revenue figure and $2.61 EPS are entirely driven by one-time accounting—specifically a $50M FDA milestone, $62.5M from a new licensing deal with Rigel, and the recognition of $112.6M in deferred revenue from Pfizer. Underneath this optical windfall, management is drastically shifting strategy. They are significantly cutting R&D spend and, surprisingly, seeking to out-license their KRAS G12D asset (ARV-806) rather than funding it themselves. Meanwhile, the crucial ARV-102 PSP trial has been delayed again to 2027.
🐂 Bull Case
The FDA approval of VEPPANU proves that heterobifunctional protein degradation works in human disease. This severely de-risks the underlying PROTAC technology for the rest of the pipeline.
Out-licensing VEPPANU to Rigel offloads launch costs and commercial execution risk, allowing Arvinas to preserve its $567.9M cash pile exclusively for its early-stage R&D engine.
🐻 Bear Case
Seeking a partner for ARV-806 (KRAS G12D) suggests Arvinas either lacks the capital or the confidence to advance this highly competitive asset alone, capping future upside.
The ARV-102 Phase 1b trial in PSP, a key non-oncology value driver, has slipped again. Originally slated for H1 2026, it is now guided for 2027 following ongoing regulatory discussions.
⚖️ Verdict: ⚪
Neutral. The VEPPANU approval is a monumental scientific win, and the cash runway is secure into 2028. However, the decision to out-license ARV-806 and the continuing delays in the ARV-102 program raise serious questions about the internal execution and ultimate value of the remaining clinical pipeline.
Key Themes
PROTAC Technology Officially De-risked
The FDA approval of VEPPANU (vepdegestrant) is the first-ever approval for a PROteolysis TArgeting Chimera (PROTAC). This validates over a decade of Arvinas's foundational science. While the drug was out-licensed to Rigel, the regulatory validation of the modality provides a structural boost to confidence across the remaining wholly-owned pipeline (BCL6, LRRK2, AR, HPK1).
ARV-806 Downgraded to Out-Licensing Candidate
In a major strategic pivot, management announced plans to seek an out-licensing agreement for any additional clinical trials (including dose expansion or combinations) for ARV-806 (KRAS G12D). Previously touted alongside BCL6 and LRRK2 as a core internal value driver, this signals an unwillingness or inability to fund expensive, highly competitive oncology efficacy trials. Competing in the KRAS space against heavily capitalized peers like RevMed likely forced this macro-driven defensive maneuver.
ARV-102 PSP Trial Timeline Slips Again
The clinical timeline for the oral PROTAC LRRK2 degrader is deteriorating. In FY25, management projected a Phase 1b start in progressive supranuclear palsy (PSP) for H1 2026. Following an FDA clinical hold in Q1 2026 requiring non-human primate tox data, the timeline shifted to late 2026. The current release explicitly states plans to initiate clinical trials in PSP are now pushed to 2027. This contradicts the narrative of rapid pipeline advancement.
Strict Cost Discipline Extending Runway
The company continues to execute flawlessly on expense management. GAAP R&D fell to $52.6M (down from $68.6M YoY). Non-GAAP R&D was $51.4M. This $16M YoY quarterly saving is driven by a $10.6M drop in VEPPANU program costs and $11M in unallocated personnel costs. The restructuring implemented in 2025 is clearly paying off, shielding the balance sheet.
ARV-393 (BCL6) Advancing on Two Fronts
ARV-393 remains the premier wholly-owned oncology asset. The Phase 1 trial continues dose escalation with observed clinical activity in B- and T-cell lymphomas below predicted effective exposures. Crucially, the combination trial with glofitamab in diffuse large B-cell lymphoma (DLBCL) is actively enrolling, setting up a major dual data catalyst for mid-2027.
Other KPIs
Reversing. While total revenue exploded YoY ($24.7M vs $22.4M), it is entirely low-quality, non-recurring accounting artifacts. The breakdown: $126.4M in recognized remaining deferred revenue from Pfizer, $62.5M from the Rigel License Agreement, and a $50M FDA approval milestone. This is a one-time cash and accounting injection, not a sustainable sales trajectory.
Stable. The balance declined from $614.9M in 26Q1, representing roughly $47M in sequential burn. However, operating cash burn for the first six months of the year was $114.3M, which was partially offset by a $35M near-term receipt from the Rigel deal. Despite the headline drop, the company remains highly capitalized for an early-stage biotech.
Guidance
Stable. Management reiterated that current cash balances are sufficient to fund operations into 2H 2028. This assumes no major out-of-pocket commercialization expenses and relies on the reduced R&D burn rate.
Decelerating. A clear downgrade from prior expectations of a late 2026 start. Management noted they will 'continue discussions with global health authorities', implying the FDA clinical hold (or ex-US equivalents) remains an active hurdle.
Accelerating. The immuno-oncology HPK1 degrader is on track for imminent clinical entry, hitting the previously stated 'mid-2026' guidance window.
Stable. The company reiterated plans to share initial data from the dose escalation trial before the end of the year, which will now serve as a 'showcase' to attract a licensing partner rather than a precursor to internal Phase 2 trials.
Key Questions
Rationale for ARV-806 Out-Licensing
With a cash runway into 2028, why are you actively seeking an out-licensing partner for ARV-806 before generating efficacy data in dose expansion? Does this reflect a lack of capital, or concerns over competitiveness in the rapidly evolving KRAS G12D landscape?
ARV-102 Clinical Hold Status
The timeline for the PSP trial of ARV-102 has slipped to 2027. What specific ongoing requirements are the 'global health authorities' requesting, and has the FDA removed the clinical hold regarding non-human primate toxicology data?
Rigel Deal Near-Term Economics
Of the $62.5M in revenue recognized from the Rigel License Agreement, how much represents upfront cash already received versus milestones that will hit the balance sheet in future quarters?